Drug giant Novo Nordisk just reported some clinical trial data. Despite the seemingly good news, the stock crashed right afterward. There's a difference between a clinical success and a ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the ...

Novo Nordisk's Attempt to Overtake Rival Eli Lilly in the Booming Obesity Medicine Market Fails. This Led to the Company's Shares Falling by a Record on Friday. Pritish Nandy, veteran poet and ...

Shares in Novo Nordisk fell yesterday, after it revealed disappointing results from a late-stage trial of its next-generation obesity drug CagriSema, wiping as much as $125bn (€120bn ...

Novo Nordisk reported on Friday that its experimental obesity drug, CagriSema, achieved a 22.7% weight reduction in overweight patients during a late-stage trial. This figure is lower than the 25% ...

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug. RFK Jr. hit an ...

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados decepcionantes de una de las drogas con las que esperaba superar a su ...

Novo Nordisk (NYSE:NVO)'s new weight loss drug CagriSema missed the company's target of reducing at least 25% body weight of the Phase 3 trials' participants. CagriSema only showed an average 22.7% of ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...